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ABSTRACT
OBJECTIVE
To evaluate the effectiveness and cost effectiveness 
of a complex intervention in primary care that aims to 
increase uptake of hepatitis C virus (HCV) case finding 
and treatment.
DESIGN
Pragmatic, two armed, practice level, cluster 
randomised controlled trial and economic evaluation.
SETTING AND PARTICIPANTS
45 general practices in South West England (22 
randomised to intervention and 23 to control arm). 
Outcome data were collected from all intervention 
practices and 21/23 control practices. Total number 
of flagged patients was 24 473 (about 5% of practice 
list).
INTERVENTION
Electronic algorithm and flag on practice systems 
identifying patients with HCV risk markers (such as 
history of opioid dependence or HCV tests with no 
evidence of referral to hepatology), staff educational 
training in HCV, and practice posters/leaflets to 
increase patients’ awareness. Flagged patients 
were invited by letter for an HCV test (with one 
follow-up) and had on-screen pop-ups to encourage 
opportunistic testing. The intervention lasted one 
year, with practices recruited April to December 2016.
MAIN OUTCOME MEASURES
Primary outcome: uptake of HCV testing. Secondary 
outcomes: number of positive HCV tests and yield 
(proportion HCV positive); HCV treatment assessment 
at hepatology; cost effectiveness.
RESULTS
Baseline HCV testing of flagged patients (six months 
before study start) was 608/13 097 (4.6%) in 
intervention practices and 380/11 376 (3.3%) in 
control practices. During the study 2071 (16%) of 
flagged patients in the intervention practices and 
1163 (10%) in control practices were tested for HCV: 
overall intervention effect as an adjusted rate ratio of 
1.59 (95% confidence interval 1.21 to 2.08; P<0.001). 
HCV antibodies were detected in 129 patients from 
intervention practices and 51 patients from control 
practices (adjusted rate ratio 2.24, 1.47 to 3.42) 
with weak evidence of an increase in yield (6.2% v 
4.4%; adjusted risk ratio 1.40, 0.99 to 1.95). Referral 
and assessment increased in intervention practices 
compared with control practices (adjusted rate ratio 
5.78, 1.6 to 21.6) with a risk difference of 1.3 per 
1000 and a “number needed to help” of one extra HCV 
diagnosis, referral, and assessment per 792 (95% 
confidence interval 558 to 1883) patients flagged. 
The average cost of HCV case finding was £4.03 
(95% confidence interval £2.27 to £5.80) per at risk 
patient and £3165 per additional patient assessed at 
hepatology. The incremental cost effectiveness ratio 
was £6212 per quality adjusted life year (QALY), with 
92.5% probability of being below £20 000 per QALY.
CONCLUSION
HepCATT had a modest impact but is a low 
cost intervention that merits optimisation and 
implementation as part of an NHS strategy to increase 
HCV testing and treatment.
TRIAL REGISTRATION
ISRCTN61788850.
Introduction
Hepatitis C virus (HCV) infection, predominantly 
transmitted by exposure to blood, is a major cause 
of chronic liver disease and cirrhosis.1 2 More than 
100 000 people in England are estimated to have 
chronic HCV infection, and more than 85% of these 
infections were acquired through injecting drug use.3
Chronic HCV infection can now be cured in more 
than 95% of patients with a range of highly tolerable, 
single pill a day, short regimen (8-12 weeks) direct 
acting antiviral agents.4-6 Consequently, the World 
Health Organization developed a strategy to eliminate 
HCV as a public health threat,7 setting targets for 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Chronic hepatitis C virus (HCV) infection can now be cured in more than 95% of 
patients
HCV case finding is critical for NHS England to increase HCV treatment and 
eliminate HCV as a public threat by 2025, five years before the WHO target
Economic models and guidance recommending increasing HCV testing for at risk 
patients in primary care are not based on robust evidence
WHAT THIS STUDY ADDS
HepCATT is complex intervention based around an electronic algorithm 
integrated with primary care practice systems that identifies and flags patients 
with risk markers of HCV infection
HepCATT can increase HCV case finding by a modest amount and be highly cost 
effective
The intervention would benefit from being optimised before implementation 
across UK primary care
 o
n
 4 M
arch 2020 at University of Nottingham
. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m322 on 26 February 2020. Downloaded from 
RESEARCH
2 doi: 10.1136/bmj.m322 | BMJ 2020;368:m322 | the bmj
decreasing the incidence of HCV by 80% and HCV 
related mortality by 65% by 2030.8 NHS England aims 
to achieve the WHO goals by 2025.
Since 2016 more than 10 000 people a year have been 
treated for HCV and an estimated 50 000 people have 
been diagnosed as having it, although many of these 
may not have been assessed or be under management 
by HCV services.3 9 Primary care is the largest source 
of HCV testing, comprising nearly 30% of all HCV 
antibody positive tests in laboratory surveillance.10
The UK’s National Institute for Health and Care 
Excellence (NICE) suggests that interventions to 
increase case finding in drug treatment centres and 
primary care are likely to be cost effective.11 However, 
robust evidence from randomised controlled trials 
on such interventions is lacking, and rates of case 
finding and drug treatment at many sites are low.12 13 
For instance, NICE’s recommendations and economic 
models were based on a small uncontrolled study in 
eight practices (selected from areas of high deprivation 
and high prevalence of injecting drug use).14
We sought to update the evidence on HCV case 
finding in primary care and conduct a cluster 
randomised controlled trial, at general practice level, 
to establish whether a complex intervention to identify 
and invite patients at high risk of HCV was effective 
and cost effective at increasing HCV case finding and 
referral of people with HCV disease for assessment at 
specialist services.
Methods
HepCATT (Hepatitis C Assessment Through to 
Treatment Trial) was a pragmatic, two armed, practice 
level, cluster randomised controlled trial carried out 
in general practices in the South West of England 
with both qualitative and economic evaluation 
components.15 The nested qualitative study is reported 
separately.16
Randomisation
General practices were the unit of allocation and were 
randomised by an independent statistician in a 1:1 ratio 
to either receive the intervention or continue care as 
usual (control group). Randomisation was stratified by 
area (Bristol and non-Bristol, in case differences existed 
at baseline between city and semi-rural practices) and 
minimised by current rate of HCV testing as measured 
by Public Health England laboratory surveillance (high 
(≥1% of practice list) versus low (<1%)) and practice 
size.10 Minimisation retained a random element such 
that each practice being allocated was more likely to 
be, but was not inevitably, allocated to the group that 
achieved the best balance in HCV testing and practice 
size between intervention and control groups. Of 93 
practices in our target area, 15 (16%) had high HCV 
testing rates.
Intervention
The intervention (registered: http://www.isrctn.com/
ISRCTN61788850) follows NICE recommendations.17 
It is described in more detail in our protocol15 (and in 
the supplementary material). In brief, the intervention 
had multiple components. (1) HCV audit tool and 
patient flag: we designed a new algorithm for the Audit+ 
software (Informatica Systems Ltd), which is fully 
integrated with primary care systems once installed 
in practices and would identify and flag patients with 
high risk HCV markers (see supplementary material 
for a full list of risk markers and associated Read 
codes). The audit tool automatically aims to exclude 
any patients tested less than one year previously 
who were negative for HCV antibodies, referred to 
hepatology, receiving low doses of buprenorphine and 
methadone for pain management, or at end of life. (2) 
Training was provided in use of the HCV audit tool. We 
recommended that practices should first screen their 
list of patients and exclude on the system any patient 
for whom they thought that an invitation for HCV 
testing or discussion of treatment was not appropriate. 
Then eligible patients should be offered HCV testing 
either opportunistically (responding to on-screen 
pop-ups) or through encouragement to book an HCV 
test by letter generated automatically by the software 
(see supplementary material). We also recommended 
that patients should be followed up to arrange 
appointments. (3) Educational training: practice 
staff were encouraged to make use of free online HCV 
educational resources (eg, Royal College of General 
Practitioners e-learning module: https://elearning.
rcgp.org.uk/). (4) Raising patients’ awareness: 
information posters and leaflets, produced by the HCV 
Trust, were provided to practices. (5) Clinical history: 
practices were encouraged to add a question about 
injecting drug use to their new patient registration.
Practices delivered this intervention over a 12 month 
study period. Patients with a positive antibody test were 
managed according to local practice, which would be 
referral to specialist services unless contraindications 
were present. Practice start date varied from April to 
December 2016.
Control practices continued to do opportunistic HCV 
case finding as usual. We contacted control practices 
only at the time of randomisation and at the end of the 
intervention period when we asked them to install and 
run the same HCV audit to generate outcome data. The 
control practices also were given a one year licence for 
the Audit+ software.
Outcomes
The main outcome was uptake of HCV testing. The 
secondary outcomes were yield (number of HCV 
positive tests and proportion of HCV tests that were 
positive), and referral and assessment for treatment of 
patients with chronic HCV at hepatology.
We collected outcomes and data on patients’ risk 
profile from general practices by using the Audit+ 
software in the intervention practices and control 
practices and linked them, using patient identifiers, 
with Public Heath England laboratory data on HCV test 
results (HCV antibody and polymerase chain reaction). 
We identified patients assessed in hepatology by linking 
HCV tests—that is, a viral load test in secondary care 
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following both positive HCV antibody and polymerase 
chain reaction tests in primary care (validated 
previously as a measure of HCV treatment referral and 
assessment18)—for our final report to funders. This was 
a change from our protocol in relation to secondary 
care to save time because of delays in obtaining 
data from controls owing to changes in research 
governance. We subsequently confirmed assessment 
through linkage between the laboratory and specialist 
services. In a sensitivity test, we linked HCV antibody 
tests in primary care to polymerase chain reaction tests 
in secondary care, as some polymerase chain reaction 
tests in primary care were missing.
Sample size calculation
In our original calculation, we assumed that an average 
practice would have a list of 4225 adult patients aged 
15-65 years, of whom approximately 1% (n=42) would 
have an injecting drug history, and that 40% (n=17) 
of these would be HCV positive. We consequently 
assumed that at least 10 patients would be identified 
as at high risk in each practice. We assumed an intra-
cluster correlation coefficient of 0.05 and hence a 
design effect of 1.45 to accommodate variation in 
antibody testing rates across practices. We needed, 
therefore, a sample size of 46 practices (23 intervention 
and 23 control; 230 patients at high risk identified in 
each arm) to detect a true absolute difference in HCV 
antibody testing uptake of 12% (from 5% to 17% of 
patients at high risk identified), with 90% power at the 
5% significance level.14 19
Statistical analysis
The trial cohort comprised those patients identified as 
at high risk by the HCV audit tool. Analyses followed 
the intention to treat principle, with practices being 
analysed in the groups to which they were randomly 
allocated. We used Stata statistical software version 
15.1 for all analyses. The primary analysis was pre-
specified before collection of the outcome data.15 
We estimated the proportion of patients with high 
risk markers tested for HCV antibodies, compared 
between intervention and control arms as a rate ratio, 
in a random effects Poisson regression model (random 
effects assumed to be normally distributed), adjusted 
for potentially prognostic variables used to stratify the 
random allocation (site of practice, HCV testing rate at 
baseline). This regression model accommodated any 
additional variation in the outcome measure between 
practices by incorporating an extra parameter and 
also allowed for the shorter follow-up period at two 
practices by including practice follow-up time as 
an offset term. The use of a mixed effects Poisson 
model is a variation to the analysis pre-specified in 
the protocol,15 in which we stated that we would be 
using negative binomial regression. Mixed effects 
Poisson regression models, by allowing a multi-
level model, more easily accommodate covariates 
at both the practice and individual levels. Both 
approaches are elaborations of Poisson regression, 
the key difference being that the negative binomial 
model assumes a γ distribution of testing rates 
across practices. In fact, the observed distribution of 
antibody testing rates was closer to a γ distribution 
than to a normal distribution, but repeating the 
analyses with practice level covariates using each 
of the two methods in turn gave practically identical 
results. We adapted this approach to the secondary 
outcome measures. The model was extended with the 
addition of an interaction term to compare the effect 
of the intervention on the primary outcome between 
subgroups specified in terms of being at high risk 
owing to opioid dependence/ injecting drug use or 
being at high risk owing to one of the other factors 
(exploratory analysis). We present a crude estimate 
of the risk difference for the primary outcome with 
95% confidence interval (calculated by making the 
normal approximation), with, at the suggestion of a 
reviewer, an adjusted risk difference estimated using 
Stata’s adjrr.20
Economic analysis
Our economic evaluation first estimated the cost per HCV 
test and referral from the trial and practice perspective 
and then estimated the cost per quality adjusted life 
year (QALY) gained associated with the intervention 
by using an existing Markov model.21 22 Both analyses 
were performed from the NHS perspective, with results 
presented in pounds sterling in 2017. Full details of 
the economic evaluation methods are given in our 
protocol15 and supplementary material.
Briefly, for the within trial analysis, we compared 
costs between intervention and control practices by 
using mixed effects linear regression, clustered by 
practice, adjusting for sampling stratification and 
length of follow-up. We estimated the cost of HCV case 
finding per patient at high risk identified through the 
HCV algorithm and calculated the incremental cost 
per patient assessed at secondary care in intervention 
versus control practices. We used a cost effectiveness 
acceptability curve to explore uncertainty.23 In a 
second analysis, we removed the costs and the Audit+ 
installation, training, and maintenance costs, as 
Audit+ is now routinely available to general practices 
with much wider functionality than just HCV case 
finding.
In the economic model, we compared the HepCATT 
intervention versus current practice, using a Markov 
model over a lifetime time horizon. We assumed that 
the intervention was implemented for one year in a 
static cohort. The model produces incremental cost 
effectiveness ratios (ICERs) per QALY gained, with both 
costs and QALYs discounted at 3.5%,24 and estimates 
the probability of cost effectiveness at a willingness 
to pay threshold of £20 000 per QALY for the NHS. We 
did multiple scenario and sensitivity tests (excluding 
training costs; assuming lower health utility values 
associated with opioid dependent people; assuming 
linkage to care for each arm was equal; halving 
estimated HCV direct acting antiviral treatment cost to 
£5000 per course). We also did a “threshold analysis” 
to estimate the minimum increase in HCV antibody 
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testing needed for the intervention to remain cost 
effective. Table 1 shows the economic inputs.
Patient and public involvement
During the set-up of the trial, we consulted with 
Bristol Drugs Project (BDP) and its volunteer group, 
which included current and previous drug injectors 
and people with HCV infection. Members of the BDP 
volunteer group reviewed the invitation letter sent by 
practices to invite patients for an HCV test and the 
patient information sheet. The information resources 
were developed in conjunction with the Hepatitis C 
Trust patient group and National Hepatitis C Patient 
Council. The Hepatitis C Trust and BDP will also 
help us to co-produce a summary of the study and 
support dissemination of findings with patients and 
practitioners
Results
Practice recruitment
The NIHR South West of England Clinical Research 
Network invited 90 practices across Bristol, North 
Somerset, and Gloucestershire; 45 practices agreed, 
and 22 were randomised to the intervention and 23 
to the control arm. Figure 1 shows the CONSORT flow 
diagram. The intervention and control practices were 
comparable in mean list size, area deprivation score, 
and proportion of the local community of non-white 
ethnicity. None of the intervention practices opted 
to ask new patients about injecting drug use history 
at registration; 15/22 practices carried out all of the 
other elements of the intervention (fig 1). Outcome 
and risk algorithm data were collected from all of the 
22 intervention practices and 21/23 control practices. 
Two intervention practices merged during the study 
period, which we treat as one in our analyses.
HCV audit risk algorithm
The total number of patients identified in both control 
and intervention practices was 24 473—approximately 
5% of the patient list, varying from 0.2% to more than 
13% by practice (supplementary table S1A and S1B). 
Table 2 shows the frequency with which each of the risk 
criteria was met by the patients identified, with 8838 
(36%) meeting two or more criteria. The proportion 
of patients identified with an opioid/injecting drug 
use history was approximately 1%, ranging from 
less than 0.1% to more than 6%. More than half of 
the cohort had evidence of a previous HCV test (63% 
in intervention and 57% in control practices). Other 
common criteria were a history of injecting or opioid 
drug use (2930 (22%) in intervention and 3315 (29%) 
in control practices) and unexplained elevated alanine 
aminotransferase concentrations.
HCV testing
Pre-intervention
At baseline, in the six month period immediately 
before the study period, 608/13 097 (4.6%) of the 
patients in the intervention practices and 380/11 376 
(3.3%) of those in the control practices who were 
identified by the algorithm were tested for HCV. HCV 
testing for patients identified with opioid/injecting 
drug use history was 69/2930 (2.4%) and 48/3315 
(1.4%) in the six months before the intervention in 
intervention and control practices respectively.
Post-intervention
During the study period, 2071 (16%) of patients 
identified in the intervention practices and 1163 
(10%) of those in control practices were tested for 
HCV (table 3). We found strong evidence of a higher 
rate of antibody testing in the intervention practices 
(adjusted rate ratio 1.59, 95% confidence interval 
1.21 to 2.08; P<0.001) compared with the control 
practices. The magnitude of this intervention effect 
was unaffected by adjustment for practice location 
and historical HCV testing rate. We estimated the 
crude risk difference to be 5.6% (95% confidence 
interval 4.8% to 6.4%), and the adjusted estimate with 
variation between general practices accommodated 
was 5.3% (2.2% to 8.51%).
Table 1 | Unit costs (2016/17) used in economic analysis and Markov model
Item Unit cost Source
Cost of Audit+ (per practice) £500 (£0 in sensitivity analysis) Assumption
Trainer time (per hour) £53 Estimate
Trainer travel expenses (per mile) £0.45 University of Bristol policy
GP time (per hour) £137 Unit costs of health and social care
Administrative staff (band 2) time (per hour) £23 Unit costs of health and social care
Healthcare assistant (band 2) £23 Unit costs of health and social care
Nursing staff (band 6) £44 Unit costs of health and social care
Practice manager (band 7) £53 Unit costs of health and social care
Phlebotomy appointment £14.10 Based on private practice (SE Bridge Street  
Medical Centre)
HCV antibody blood test £8.12 Public Health England
HCV PCR blood test £ 90.64 Public Health England
HCV related GP consultation £37 Unit costs of health and social care
Hepatology consultation £219 NHS reference costs
Hepatology evaluation (outpatient, initial) £238 NHS reference costs
Hepatology evaluation (outpatient, follow-up) £262 NHS reference costs
DAA treatment (first treatment) £10 000 Hurley 2018
DAA treatment (retreatment) £15 000 Assumption
DAA treatment monitoring £1,310 NHS reference costs
DAA=direct acting antiviral; GP=general practitioner; HCV=hepatitis C virus; PCR=polymerase chain reaction.
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In an exploratory analysis, also shown in table 3, 
we found that the intervention had a slightly greater 
effect on patients with an opioid/injecting drug use 
history (adjusted rate ratio 2.73) than other patient 
risk groups (adjusted rate ratio 1.45), with evidence 
against the null hypothesis of equal intervention rate 
ratios between the two subgroups (interaction test 
P<0.001). The crude risk differences, however, were 
similar in the two subgroups at 4-5%.
We estimate that the intra-cluster correlation 
coefficient was 0.067 (95% confidence interval 0.042 
to 0.105) on the basis of a random effects logistic 
regression model (with the same covariates as the 
adjusted model in table 3) to allow comparison with 
the estimate used in the sample size calculation.
Other outcomes: HCV test yield, chronic infection, 
referral and assessment
The rate of positive antibody tests was also greater in 
the intervention practices compared with the control 
practices (table 3) (1.0% v 0.5%; adjusted rate 
ratio 2.24, 1.47 to 3.42). A greater proportion of the 
antibody tests were positive in the intervention group 
(6.4%; 129/2017) than in the control group (4.4%; 
51/1163), although the evidence was weaker and 
consistent with chance (adjusted risk ratio 1.40, 0.99 
to 1.95; P=0.053).
Of those people with a positive antibody test, no 
polymerase chain reaction tests were recorded for 
9/129 patients in intervention practices and 1/51 
patients in the control practices, and insufficient 
Invited to participate in HepCATT
Practices allocated to controlPractices allocated to intervention
High HCV testing ≥1% practice list (n=4) v
low HCV testing <1% practice list (n=18)
Bristol (n=13) v non-Bristol (n=9)
No practices asked for injecting history at
  registration
Carried out other components of intervention
  in full (n=15)
High HCV testing ≥1% practice list (n=6) v
low HCV testing <1% practice list (n=17)
Bristol (n=14) v non-Bristol (n=9)
Usual care
Lost to follow-up
Practices merged with two other
  practices not involved in study
Practices received HepCATT
  intervention for 9 months instead of
  1 year owing to problems with set-up
  of Informatica soware
2
2
AnalysisAnalysis
Declined to participate
2322
2122
Randomised
0
Lost to follow-up
Practices changed GP systems that
  were not compatible with Informatica
  soware
2
2
45
90
45
Fig 1 | Consort diagram. No practices added “have you ever injected recreational drugs?” to their patient registration 
proforma. Mean patients registered: intervention 11 225 (SD 4245), control 10 937 (3916); mean area deprivation 
score: intervention 6 (3.26), control 6 (3.23); mean % non-white ethnic population: intervention 12 (14.25), control 11 
(11.49). GP=general practice; HCV=hepatitis C virus
Table 2 | Number of participants in intervention and control practices meeting each hepatitis C virus (HCV) audit 
criterion. All cohort members met one or more criteria
HCV audit criteria
Intervention (n=13 097):  
positive risk criteria (%)
Control (n=11 376):  
positive risk criteria (%)
History of HCV exposure or testing 8295 (63.3) 6476 (56.9)
History of opioid/injecting drug use 2930 (22.4) 3315 (29.1)
History of HIV or HBV infection 971 (7.4) 829 (7.3)
History of blood transfusion or transplant 423 (3.2) 378 (3.3)
History of childhood in care or imprisonment 899 (6.9) 1024 (9.0)
Altered ALT concentration 5120 (39.1) 3895 (34.2)
ALT=alanine aminotransferase; HBV=hepatitis B virus.
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sample (no result) was recorded for an additional 
17 intervention and 14 control patients. Evidence of 
chronic disease from polymerase chain reaction tests 
in primary care, in people with a positive antibody test, 
was detected in 43 (0.3%) in intervention practices 
and 13 (0.1%) in control practices (table 3) (adjusted 
rate ratio 2.96, 1.34 to 6.58).
We found strong evidence that referral and 
assessment were increased in intervention practices 
compared with control practices (adjusted rate ratio 
5.78, 1.55 to 21.6). The absolute difference between 
intervention and control practices, however, was 
modest: 20/43 patients with HCV RNA detected or 15 
in 10 000 patients at high risk in intervention practices, 
compared with 3/13 or 3 in 10 000 patients at high 
risk from control practises. This equates to a number 
needed to help of one extra HCV diagnosis, referral, 
and assessment per 792 (95% confidence interval 
558-1883) patients flagged. In a sensitivity analysis 
relaxing the requirement for a positive polymerase 
chain reaction test from primary care, the intervention 
effect was slightly attenuated but still strong (adjusted 
rate ratio 3.40, 1.35 to 8.52).
Change in baseline HCV testing: potential 
contamination/dilution of effect
Supplementary table S1A shows evidence that HCV 
testing increased in general in the community. Overall 
and in 18/21 of the control practices, the number and 
proportion of HCV tests among patients at high risk 
in the six months before the intervention (380; 3.3%) 
more than doubled during the intervention period 
(1163; 10.2%). We found no evidence that testing 
increased over time in control practices among patients 
with an opioid/injecting drug use history (HCV testing 
in this patient group was 1.4% in the six months before 
the intervention and 2.4% in the 12 months during the 
intervention).
Economic evaluation
A small number of patients (287/24 473 (1.2%) 
appeared in the records of more than one practice. 
We retained these in the analysis of the intervention 
effect reported above to avoid excluding a more mobile 
section of the study sample but excluded them from the 
economic analysis, which is based on the remaining 
23 896 patients (12 922 in the intervention arm and 
10 974 in the control arm).
High variability existed between practices in the 
time estimated to complete each stage of the case 
finding process (supplementary table S2). The most 
time consuming stage was screening the list of patients 
to identify appropriate candidates for the screening 
invitation; this varied from an estimated one hour 
to 30 hours. This stage was also the most expensive, 
as the task was most often carried out by a general 
practitioner. Other elements of the case finding were 
more often carried out by the practice manager or 
administrative staff. The mean total cost of the case 
finding process was £1272 per practice, or £624 per 
practice if software and installation costs are excluded.
The intervention led to a very small increase in the 
number and the cost of HCV related general practice 
consultations during the study period, but this had 
little effect on total costs (table 4). The additional cost 
of case finding per patient at risk in the intervention 
practices was £7.10 (95% confidence interval £4.75 
to £9.45). The average cost per additional patient 
Table 3 | Hepatitis C virus (HCV) antibody testing, HCV positive test yield, polymerase chain reaction (PCR) tests for 
chronic infection, and referral to secondary care in intervention and control practices, with intervention effect estimated 
as rate ratio from random effects Poisson regression model that accommodates any variations in testing between 
practices
Number (%)
Rate ratio (95% CI) P valueIntervention (n=13 097) Control (n=11 376)
Tested
Crude 2071 (15.8) 1163 (10.2) 1.57 (1.18 to 2.09) 0.002
Adjusted* 1.59 (1.21 to 2.08) <0.001
Subgroup analysis†:
 Opioid/injecting drug use 189/2930 (6.5) 80/3315 (2.4) 2.73 (1.95 to 3.82) -
 No opioid/injecting drug use 1882/10 167 (18.5) 1083/8061 (13.4) 1.45 (1.08 to 1.95) -
Ratio of rate ratios‡ - - 1.91 (1.45 to 2.52) <0.001
Antibody test positive
Crude 129 (1.0) 51 (0.4) 2.30 (1.41 to 3.75) 0.001
Adjusted* 2.24 (1.47 to 3.42) <0.001
PCR test positive
Crude 43 (0.3) 13 (0.1) 3.17 (1.38 to 7.31) 0.007
Adjusted* 2.96 (1.34 to 6.58) 0.008
Referred/positive antibody and PCR tests
Crude 20 (0.2) 3 (<0.1) 6.25 (1.67 to 23.38) 0.007
Adjusted* 5.78 (1.55 to 21.61) 0.009
Referred/positive antibody test (sensitivity analysis)
Crude 27 (0.2) 7 (<0.1) 3.43 (1.36 to 8.65) 0.009
Adjusted* 3.40 (1.35 to 8.52) 0.009
*Adjusted for practice location (Bristol versus elsewhere) and historical HCV testing rate (low versus high, as indicated by Public Health England).
†Subgroups defined by history of opioid/injecting drug use.
‡Estimated ratio of rate ratios in two subgroups (opioid/injecting drug use and no opioid/injecting drug use, and control practices as reference within 
each), with interaction test P value estimated from model with covariates as in above*.
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referred to hepatology for assessment was £5569. 
Figure 2 shows the cost effectiveness acceptability 
curve based on the cost per additional case identified. 
Alternatively, after exclusion of the training, software, 
and installation costs, the cost of case finding was 
£4.03 (£2.27 to £5.80) and the average cost per 
additional patient referred to hepatology for treatment 
was £3165.
Economic model
Table 5 shows the estimated ICERs per QALY gained 
from the economic model. The base case analysis 
generated an ICER of £7431 per QALY with a probability 
of 89.7% of being below £20 000 per QALY (fig 3). 
After exclusion of training and installation costs, the 
ICER was £6212 per QALY (with 92.5% probability of 
being below £20 000 per QALY). Table 5 also shows 
our sensitivity analyses. The intervention was still cost 
effective when we assumed no effect of the intervention 
on the linkage to care (ICER £19 653 per QALY) and 
a reduced utility in patients who may continue to be 
opioid dependent and/or inject drugs (ICER £9093 per 
QALY) and was more cost effective when we assumed 
lower HCV drug costs (ICER £5641 per QALY).
Threshold analyses
In our threshold analysis of the effect of the intervention 
on the rate ratio of antibody testing, the base case 
analysis will always be cost effective at an ICER less 
than £20 000 per QALY because the intervention led to 
higher linkage to care. If we assume that linkage to care 
was equal for control and intervention practices, then 
the cost effectiveness threshold for the intervention 
effect of increasing HCV antibody testing was a rate 
ratio of 1.56 (or a 56% increase in HCV testing).
Discussion
The size of the effect of the HepCATT primary care 
intervention was comparatively modest but at low cost 
to the NHS. The risk difference was 1.3 per 1000 or a 
“number needed to help” of one extra HCV diagnosis, 
referral, and assessment per 792 patients flagged on 
primary care systems. A threefold to sixfold increase 
in linkage to specialist care occurred. The intervention 
cost was £624 per practice (with software and 
installation costs removed as the HCV audit tool is 
now incorporated in many clinical software systems) 
equating to approximately £4.03 per patient flagged, 
an average cost per additional patient referred to HCV 
specialist services of £3165 and an ICER of £6212 
per QALY (well below NICE’s guidance of £20 000 per 
QALY or even the average cost of NHS treatments of 
approximately £13 000 per QALY25).
Limitations of study
Overall, the trial was completed as planned, but some 
potential limitations to the study exist. Firstly, we 
detected some evidence of contamination between 
control and intervention sites. A clear increase in HCV 
testing during the intervention period occurred among 
people with a previous HCV test in the control practices, 
but we found no evidence of any increase in testing 
in those with an opioid/injecting drug use history. 
This was probably due to increased steps nationally 
and regionally to increase HCV testing as part of HCV 
treatment targets for operational delivery networks. 
Nevertheless, the HepCATT intervention managed to 
increase uptake of HCV testing and increased linkage 
to care.
Secondly, our sample size calculations had assumed 
that around 10 people at high risk would be identified 
per practice and that we would have sufficient power 
to detect a difference in HCV testing between 5% in the 
control group to 17% in the intervention group. In our 
trial, the average number of patients flagged (across 
control and intervention practices) was more than 
Table 4 | Cost effectiveness of hepatitis C virus (HCV) case finding
Task Intervention (n=12 922) Control (n=10 974) Difference (95% CI)
Training cost £1.22 £0 - 
Screening cost £2.06 £0 -
Mean HCV antibody test cost per patient £3.54 £2.33 £1.21 (£1.02 to £1.40)
Mean HCV PCR test cost per patient £0.89 £0.41 £0.48 (£0.28 to £0.68)
No (%) HCV related consultations: no; yes 12 187 (94); 735 (6) 10 467 (95); 507 (5)
Mean HCV related consultation cost per patient £2.27 £2.10 £0.17 (–£0.09 to £0.44)
Mean hepatology referral cost per patient £0.44 £0.12 £0.32 (£0.12 to £0.52)
Total mean case finding cost per patient £10.42 £4.96 £7.10 (£4.75 to £9.45)*
No (%) patients referred to hepatology for treatment 20 (0.15) 3 (0.03) - 
Cost per additional patient referred to hepatology for 
treatment
- - £5569
PCR=polymerase chain reaction.
*Adjusted mean difference from mixed effects linear regression, clustered by practice, adjusted for previous HCV testing, Bristol practice, and length of 
follow-up.
Willingness to pay per HCV case identified and treated (£000s)
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Fig 2 | Probability that hepatitis C virus (HCV) case finding is cost effective per 
additional case identified: cost effectiveness acceptability curve
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500 and the average number of people with an opioid/
injecting drug use history was 148. The observed 
difference was smaller than anticipated, partly because 
of improvements in HCV testing in the community, and 
the intra-cluster correlation coefficient at 0.067 was 
marginally greater than our assumed 0.05, but both 
of these factors will have been more than offset by the 
greater than anticipated number of people at high risk 
found at the vast majority of practices.
Thirdly, as this was a cluster randomised controlled 
trial, we did not seek consent from individual 
patients for participation in the full study (which 
was justified as the intervention was following NICE 
recommendations). A consequence of this was that 
we did not seek patients’ consent to examine their 
records—for example, to explore reasons for the 
insufficient samples for polymerase chain reaction 
testing in so many cases.
Fourthly, general population samples tend to find 
a lower proportion of people with chronic disease 
(detectable HCV RNA/ polymerase chain reaction 
positive) than do clinical samples.26 27 In our sample—
excluding those with no polymerase chain reaction 
tests or tests with insufficient sample—we found 
that 40% had chronic HCV infection. It was not clear 
whether this was because people had been previously 
treated (but not recorded in clinical information that 
could be searched by the HCV algorithm) or had 
cleared the virus and previously been found to be HCV 
negative. This reduces the yield and potentially the 
cost effectiveness of the intervention (although the 
intervention was shown to be highly cost effective).
Other evidence
Large scale trials on HCV case finding in primary 
care are rare.13 We also did a pilot trial of NICE 
recommendations to appoint HCV case facilitators 
in community drug clinics.28 The original cost 
effectiveness model underpinning NICE guidance 
in primary care was based on a non-randomised 
pilot study in eight practices with high levels of 
deprivation.14 The earlier study used financial 
incentives for participation, searched practice lists for 
a smaller sub-group of patients with a history of opioid 
dependence, and the intervention was estimated to 
be less cost effective than ours (at an estimated ICER 
of £13 900 per QALY), although the original pilot 
generated a higher yield of patients with chronic HCV 
infection.
A recent complementary trial (HepFREE), also 
motivated by the lack of robust evidence in support of 
NICE guidance on hepatitis case finding,17 19 showed 
that combining case finding for HCV and hepatitis B 
virus in migrant populations in primary care could be 
effective and broadly cost effective.29 The HepFREE 
trial was conducted in general practices with a high 
density of migrants and involved a modest incentive 
(£500) for general practitioners to run an algorithm 
that would identify patients for contacting by letter 
and add an electronic prompt to the patient’s record. 
Additional clinical support was available to help 
practices run the case finding exercise. HepFREE also 
found a comparatively low proportion of viraemic 
patients (at approximately a third of people with 
HCV antibody tests), which as for HepCATT reduces 
the yield of the study and has implications for the 
re-engagement exercise recently launched by Public 
Health England and NHS England (https://www.gov.
Table 5 | Base case and scenario analysis results per patient identified as at high risk by HepCATT intervention
Testing option Total costs Total QALYs Incremental costs Incremental QALYs ICER
Base case results:
 Control arm £409 16.2202 - - - 
 Intervention arm £416 16.2212 £7.44 0.00100 £7431
Training costs excluded:
 Control arm £409 16.2202 - - -
 Intervention arm £415 16.2212 £6.22 0.00100 £6212
Scenario—no treatment effect for linkage to care 
(referral and attendance):
 Control arm £408 16.2206 - - -
 Intervention arm £417 16.2210 £8.44 0.00043 £19 653
Scenario: £5000 per DAA:
 Control arm £382 16.2202 - - -
 Intervention arm £388 16.2212 £5.64 0.00100 £5641
Scenario—utility adjusted to PWID utilities (all 
multiplied by 0.82):
 Control arm £409 13.2552
 Intervention arm £416 13.2561 £7.44 0.00082 £9093
DAA=direct acting antiviral; ICER=incremental cost effectiveness ratio; PWID=people who inject drugs; QALY=quality adjusted life year.
Willingness to pay per QALY gained (£000s)
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Fig 3 | Probabilistic sensitivity analysis that hepatitis C virus case finding is cost 
effective at different thresholds of willingness to pay per quality adjusted life year 
(QALY)
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uk/government/publications/hepatitis-c-patient-re-
engagement-exercise).
A previous study in Ireland found an increase in HCV 
testing in general practices that were encouraged to 
follow clinical guidelines recommending HCV testing 
for patients taking methadone.30 In the UK, case finding 
and early treatment for opioid dependent patients 
has been established to be highly cost effective, and 
multiple alternative case finding and care pathways 
are being tested and developed in the community for 
this population group, including through prisons, 
pharmacies, needle exchange services, and homeless 
services.12 28 31 32 However, these care pathways do not 
cover our study patients—people in primary care who 
may no longer be opioid dependent or taking opioid 
agonist treatment.
An alternative, and possibly complementary, 
approach is to conduct birth cohort screening, whereby 
all patients born between specific years (such as 1945 
to 1965 as recommended by the Centers for Disease 
Control and Prevention in the US) are invited to be 
screened for HCV.33 34 An economic model suggests 
that adding HCV screening to the NHS health check for 
people aged 45 to 70 could be cost effective, although 
no empirical evidence yet supports such a change.35
Implications
The nested qualitative study suggests that practices 
are willing to engage with our intervention.16 Our 
intervention was highly cost effective but increased 
HCV testing by only a modest amount—lower than 
expected from our original sample size calculation. 
The overall findings are strong enough for us to 
recommend optimisation as part of implementation 
across primary care in the UK. However, HepCATT 
cannot be seen as the only solution to increasing HCV 
case finding in primary care and to identifying patients 
at risk who may not be aware of their HCV infection. 
Other interventions, such as evaluating birth cohort 
screening as part of NHS health checks, and additional 
components to the HepCATT intervention, such as 
incentives for the practices for running the algorithm 
and additional clinical support for achieving higher 
uptake, are needed to enhance the impact.
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